Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/MED.0000000000000237 http://scihub22266oqcxt.onion/10.1097/MED.0000000000000237 C5061509!5061509!26825471     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Endocrinol+Diabetes+Obes 2016 ; 23 (2): 157-64 Nephropedia Template TP {{tp|p=26825471|t=2016. Lp(a) as a new target for reduction of risk of cardiovascular disease and emergence of novel therapies to lower Lp(a) |pdf=|usr=}}{{26825471}} gab.com Text Lp(a) as a new target for reduction of risk of cardiovascular disease and emergence of novel therapies to lower Lp(a) JO: Curr Opin Endocrinol Diabetes Obes http://www.kidney.de/pget.php?&tw=1&pmid=26825471 #FOAvip Purpose of review: The purpose of this review is to summarize recent observations on the role of lipoprotein(a) [Lp(a)] as a risk factor mediating cardiovascular disease. Recent findings: Lp(a) is a highly prevalent cardiovascular risk factor, with levels >30 mg/dL affecting 20?30% of the global population. Up until now, no specific therapies have been developed to lower Lp(a) levels. Three major levels of evidence support the notion that elevated Lp(a) levels are a causal, independent, genetic risk factor for cardiovascular disease; epidemiologic studies and meta-analyses, genome wide association studies and mendelian randomization studies. Recent studies also have noted that individuals with low levels of Lp(a) are associated with a higher risk of incident type 2 diabetes mellitus, and conversely individuals with high levels have a lower risk, but this association does not appear to be causal. Novel therapies to lower Lp(a) include PCSK9 inhibitors and antisense oligonucleotides directly preventing translation of apolipoprotein(a) mRNA. Summary: With this robust and expanding clinical database, a re-awakening of interest in Lp(a) as clinical risk factor is taking place. Trials are underway with novel drugs that substantially lower Lp(a) and may reduce its contribution to cardiovascular disease. Twit Text FOAVip Lp(a) as a new target for reduction of risk of cardiovascular disease and emergence of novel therapies to lower Lp(a) ????Curr Opin Endocrinol Diabetes Obes http://www.kidney.de/pget.php?&tw=1&pmid=26825471 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26825471 #FOAvip English Wikipedia <ref>{{Cite pmid|26825471}}</ref> Lp(a) as a new target for reduction of risk of cardiovascular disease and emergence of novel therapies to lower Lp(a) #MMPMID26825471 Tsimikas S Curr Opin Endocrinol Diabetes Obes 2016[Apr]; 23 (2): 157-64 PMID26825471show ga Purpose of review: The purpose of this review is to summarize recent observations on the role of lipoprotein(a) [Lp(a)] as a risk factor mediating cardiovascular disease. Recent findings: Lp(a) is a highly prevalent cardiovascular risk factor, with levels >30 mg/dL affecting 20?30% of the global population. Up until now, no specific therapies have been developed to lower Lp(a) levels. Three major levels of evidence support the notion that elevated Lp(a) levels are a causal, independent, genetic risk factor for cardiovascular disease; epidemiologic studies and meta-analyses, genome wide association studies and mendelian randomization studies. Recent studies also have noted that individuals with low levels of Lp(a) are associated with a higher risk of incident type 2 diabetes mellitus, and conversely individuals with high levels have a lower risk, but this association does not appear to be causal. Novel therapies to lower Lp(a) include PCSK9 inhibitors and antisense oligonucleotides directly preventing translation of apolipoprotein(a) mRNA. Summary: With this robust and expanding clinical database, a re-awakening of interest in Lp(a) as clinical risk factor is taking place. Trials are underway with novel drugs that substantially lower Lp(a) and may reduce its contribution to cardiovascular disease. äLp(a) as a new target for reduction of risk of cardiovascular disease (epmc).pdf DeepDyve Pubget Overpricing